ArticleFrontiers in molecular neuroscience2018
Beneficial Effect of a Selective Adenosine A
Open access · goldAbstract read
In one paragraph
Article in Frontiers in molecular neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 89 citations in OpenAlex.
- From danger to resolution: targeting purinergic signaling in CNS diseases.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- Review
- Microglial purinergic signaling in Alzheimer's disease.Purinergic signalling · 2025Review
- An Expanded Narrative Review of Neurotransmitters on Alzheimer's Disease: The Role of Therapeutic Interventions on Neurotransmission.Molecular neurobiology · 2025Review
- Chronic Caffeine Consumption, Alone or Combined with Agomelatine or Quetiapine, Reduces the Maximum EEG Peak, As Linked to Cortical Neurodegeneration, Ovarian Estrogen Receptor Alpha, and Melatonin Receptor 2.Psychopharmacology · 2024Article
- Association of caffeine consumption with cerebrospinal fluid biomarkers in mild cognitive impairment and Alzheimer's disease: A BALTAZAR cohort study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Extracellular Purine Metabolism-Potential Target in Multiple Sclerosis.Molecular neurobiology · 2024Review
- Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.Brain : a journal of neurology · 2024Article
- Blockade of adenosine AAlzheimer's research & therapy · 2023Article
- Modification of astrocytic Cx43 hemichannel activity in animal models of AD: modulation by adenosine ACellular and molecular life sciences : CMLS · 2023Article
- Pharmacology of Adenosine Receptors: Recent Advancements.Biomolecules · 2023Review
- Xanthine-Dopamine Hybrid Molecules as Multitarget Drugs with Potential for the Treatment of Neurodegenerative Diseases.Biomolecules · 2023Article
- Caffeine for Prevention of Alzheimer's Disease: Is the ABiomolecules · 2023Review
- Crystal structure of adenosine ACommunications chemistry · 2023Article
- Action of the Purinergic and Cholinergic Anti-inflammatory Pathways on Oxidative Stress in Patients with Alzheimer's Disease in the Context of the COVID-19 Pandemic.Neuroscience · 2023Review
- Pathway-based integration of multi-omics data reveals lipidomics alterations validated in an Alzheimer's disease mouse model and risk loci carriers.Journal of neurochemistry · 2023Article
- AFrontiers in immunology · 2023Article
- Analysis of ADORA2A rs5760423 and CYP1A2 rs762551 Genetic Variants in Patients with Alzheimer's Disease.International journal of molecular sciences · 2022Article
- The Role of the Adenosine System on Emotional and Cognitive Disturbances Induced by Ethanol Binge Drinking in the Immature Brain and the Beneficial Effects of Caffeine.Pharmaceuticals (Basel, Switzerland) · 2022Review
- International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.Pharmacological reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 9 institutions in 5 countries.
Emilie FaivreUniversité de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France.
Joana E CoelhoInstituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal.
Katja ZornbachCenter of Advanced European Studies and Research, Bonn, Germany.
Enas MalikPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Younis BaqiPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Marion SchneiderPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Lucrezia CellaiUniversité de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France.
Kevin CarvalhoUniversité de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France.
Shéhérazade SebdaPlateau de Génomique Fonctionnelle et Structurale, CHU Lille, University of Lille, Lille, France.
Martin FigeacPlateau de Génomique Fonctionnelle et Structurale, CHU Lille, University of Lille, Lille, France.
Sabiha EddarkaouiUniversité de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France.
Raphaëlle CaillierezUniversité de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France.
Yijuang ChernInstitute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
Michael HenekaGerman Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
Nicolas SergeantUniversité de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France.
Christa E MüllerPharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical Chemistry I, University of Bonn, Bonn, Germany.
Annett HalleCenter of Advanced European Studies and Research, Bonn, Germany.
Luc BuéeUniversité de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France.
Luisa V LopesInstituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal.
David BlumUniversité de Lille, Inserm, CHU-Lille, LabEx DISTALZ, Jean-Pierre Aubert Research Centre UMR-S1172, Alzheimer & Tauopathies, Lille, France.
University of Bonn · DECentre de Recherche Jean Pierre Aubert · FRUniversité de Lille · FRCenter of Advanced European Studies and Research · DEInserm · FRUniversity of Lisbon · PTCentre Hospitalier Universitaire de Lille · FRInstitute of Biomedical Sciences, Academia Sinica · TWUnité de Glycobiologie Structurale et Fonctionnelle · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Consumption of caffeine, a non-selective adenosine A
Indexed as
A2Aadenosine receptorAlzheimer’s diseaseamyloidmemory
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.